Non-rheumatic degenerative mitral valve disease

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

Non-rheumatic degenerative mitral valve disease is a wear-and-tear disease of the mitral valve. Most people with early or mild disease are followed with surveillance. The treatability level is curable in some. Surgical mitral valve repair or replacement is the most important milestone—it can restore valve competence and long-term survival for people with severe, repairable disease and acceptable surgical risk. That option depends on anatomy and candidacy, so it is not available to everyone. Burden data have not yet been loaded, so a numeric trend cannot be stated here. In experienced surgical settings, severe leakage is now corrected regularly; in places without that access, it often goes untreated and worsens. Research continues: 117 trials started in the past five years and 141 are currently active.

What is non-rheumatic degenerative mitral valve disease?

It is gradual wear and tear of the mitral valve, not caused by rheumatic fever. The valve leaks or becomes deformed, and blood can move backward. Early on, people may feel nothing; severe leakage over time can strain the heart.

Can this valve disease be cured?

For a subset, yes. Severe regurgitation with repairable anatomy and acceptable risk can be fixed by surgical valve repair or replacement, restoring valve competence. Early or mild disease, and some high-risk patients, are not candidates; they are managed with surveillance and medical care.

What happens if severe leakage is left untreated?

It can lead to progressive heart failure, atrial fibrillation, and lower long-term survival. Repair or replacement changes the trajectory for suitable patients. If surgery is not possible, symptoms can be reduced but the leak itself cannot be cured.

Are new treatments under study?

Yes. There are 141 active trials, with 117 started in the last five years; only two have reached phase 3 so far. Many focus on improving repair techniques, less invasive replacement options, and identifying which patients benefit.

Has the trend for this disease improved?

No national trajectory has been confirmed yet. Well-established knowledge suggests that in regions with experienced valve surgeons, severe disease is repaired often and survival improves; in low-resource settings, severe leaks remain common reason for preventable heart failure and death.